Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Maintenance Trial

Farhad Ravandi, MBBS, Christopher Pocock, MBBS, Dominik Selleslag, MD, Pau Montesinos, MD PhD, Hamid Sayar, MD MSc, Maurizio Musso, MD, Angela Figuera Alvarez, Hana Safah, MD, William Tse, MD FACP, Sang Kyun Sohn, MDPhD, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD, Timothy Chevassut, Francesca Pierdomenico, Ignazia La Torre, Barry Skikne, MD, Keshava Kumar, PhD, Qian Dong, DrPH, C.L. Beach, PharmD, Hervé Dombret, MD

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-137669

Published: 2020

Journal Articles

CC-486 Improves Overall Survival (OS) and Relapse-Free Survival (RFS) for Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC), Regardless of Amount of Consolidation Received: Results from the Phase III QUAZAR AML-001 Maintenance Trial

Andrew Wei, MBBS,PhD, Gail J. Roboz, MD, Hervé Dombret, MD, Hartmut Döhner, Andre C. Schuh, Pau Montesinos, MD PhD, Christopher Pocock, MBBS, Dominik Selleslag, MD, Sergey N. Bondarenko, Ignazia La Torre, Barry Skikne, MD, Keshava Kumar, PhD, Qian Dong, DrPH, C.L. Beach, PharmD, Farhad Ravandi, MBBS

Blood (2020) 136 (Supplement 1): 38–40.

https://doi.org/10.1182/blood-2020-138498

Published: 2020

Journal Articles

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

Blood (2019) 134 (Supplement_2): LBA-3.

https://doi.org/10.1182/blood-2019-132405

Published: 2019

Journal Articles

Spirit 2: Final 5 Year Analysis of the UK National Cancer Research Institute Randomized Study Comparing Imatinib with Dasatinib in Patients with Newly Diagnosed Chronic Phase CML

Stephen O'Brien, MBBS, BSc, PhD MRCPath, MRCP, Leanne Cork, BSc, Valeria Bandeira, MD, Ruth Bescoby, MSc, Letizia Foroni, MD PhD, Lynn Alaily, MSc, RN, NDN, MICR, Wendy Osborne, MBBS, Helen Bell-Gorrod, BSc, Nicholas Latimer, PhD, Jane Apperley, MB ChB MD, Corinne Hedgley, BSc (Hons), Richard Syzdlo, PhD, Jennifer Byrne, MB, ChB, MRCP, MRCPath, MD, Christopher Pocock, MD PhD, Bernard Ramsahoye, MB, ChB, PhD FRCPath, MRCP, Thomas Zwingers, BSc, James Wason, PhD, Mhairi Copland, PhD MBBChir, FRCP, FRCPath, Richard Clark, MBBS, MRCP, MRCPath, MD

Blood (2018) 132 (Supplement 1): 457.

https://doi.org/10.1182/blood-2018-99-110128

Published: 2018

Journal Articles

Minimal Residual Disease Response at End of Induction and during Maintenance Correlates with Updated Outcome in the Phase III GALLIUM Study of Obinutuzumab- or Rituximab-Based Immunochemotherapy in Previously Untreated Follicular Lymphoma Patients

Christiane Pott, Eva Hoster, Britta Kehden, Michael Unterhalt, Michael Herold, Richard van der Jagt, Ann Janssens, Michael Kneba, Jiri Mayer, MD, Christopher Pocock, MD PhD, Andrea Knapp, Nathalie Danesi, Tina Nielsen, Helen Brown, Kirsten Mundt, Robert Marcus, Wolfgang Hiddemann

Blood (2018) 132 (Supplement 1): 396.

https://doi.org/10.1182/blood-2018-99-115930

Published: 2018

Journal Articles

Results of a Phase 2 Trial of the Monocyte-Targeted Histone Deacetylase Inhibitor Tefinostat (CHR-2845) in Chronic Myelomonocytic Leukemia (CMML) — the UK Monocle Study

Steven Knapper, DM, Michael Dennis, MD, MRCP, FRCPath, Mark W Drummond, PhDMD, Robert K. Hills, MA, DPhil, MSc, Richard James Dillon, MA, PhD MRCP, FRCPath, Christopher Pocock, MD PhD, Dominic J. Culligan, Paresh Vyas, Daniel Wiseman, MB, ChB, Joanna Zabkiewicz, PhD, Marie Hodges, PhD MSc, Catherine Cargo, MB, FRCPath, Jan Taylor, PhD MSc, BSc, Laura Upton, Melissa Wright, David Bowen, MD PhD

Blood (2018) 132 (Supplement 1): 1818.

https://doi.org/10.1182/blood-2018-99-110356

Published: 2018

Journal Articles

Older Patients (pts) with Previously Untreated Classical Hodgkin Lymphoma (cHL): A Detailed Analysis from the Phase 3 ECHELON-1 Study

Blood (2018) 132 (Supplement 1): 1618.

https://doi.org/10.1182/blood-2018-99-112178

Published: 2018

Journal Articles

A Comparison of Prognostic Indices in Diffuse Large B-Cell Lymphoma within the UK NCRI R-CHOP 14 Versus 21 Phase III Trial

Mary Gleeson, Nicholas Counsell, David Cunningham, Eliza Hawkes, Anthony Lawrie, Andrew Jack, Paul Smith, Christopher Pocock, MD PhD, Kirit M. Ardeshna, MB BChir, John Radford, MD FRCP, Andrew McMillan, John Davies, Deborah Turner, Anton Kruger, Peter Johnson, MD, David C. Linch

Blood (2018) 132 (Supplement 1): 2956.

https://doi.org/10.1182/blood-2018-99-111824

Published: 2018

Journal Articles

The Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma As Determined By Whole Genome Expression Profiling on Paraffin Embedded Tissue Is Independently Associated with Reduced Overall and Progression Free Survival in the Rituximab Era: Results from the UK NCRI R-CHOP 14 v 21 Phase III Trial

Blood (2016) 128 (22): 1746.

https://doi.org/10.1182/blood.V128.22.1746.1746

Published: 2016

Journal Articles

Updated Analysis of Overall Survival in Randomized Phase III Study of Idelalisib in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL

Andrew D. Zelenetz, Jennifer R. Brown, Julio Delgado, Herbert Eradat, Paolo Ghia, Abraham Jacob, Wojciech Jurczak, Javier Loscertales, Donald MacDonald, Franck Morschhauser, Javier De la Serna, Mazyar Shadman, Christopher Pocock, Adeboye Henry Adewoye, Yeonhee Kim, David Simpson, Stephan Stilgenbauer

Blood (2016) 128 (22): 231.

https://doi.org/10.1182/blood.V128.22.231.231

Published: 2016

Journal Articles

Chronic Myeloid Leukaemia Patients with Stable Molecular Responses (at least MR3) May Safely Decrease the Dose of Their Tyrosine Kinase Inhibitor: Data from the British Destiny Study

Richard E. Clark, MD, Fotios Polydoros, MSc, Jane F. Apperley, MD, Christopher Pocock, Graeme Smith, MD, Jenny L Byrne, FRCP FRCPath PhD, Stephen G. O'Brien, BSc (Hons) PhD MBChB FRCP MRCPath, Tony Coffey, Letizia Foroni, MD PhD, Mhairi Copland, BSc (Hons) MB ChB PhDFRCP FRCPath

Blood (2016) 128 (22): 938.

https://doi.org/10.1182/blood.V128.22.938.938

Published: 2016

Journal Articles

A Prospective Randomised Trial of Targeted Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) Based upon Real-Time Gene Expression Profiling: The Remodl-B Study of the UK NCRI and SAKK Lymphoma Groups (ISRCTN51837425)

Andrew J Davies, MRCP PhD, Josh Caddy, Tom Maishman, Sharon Barrans, PhD, Christoph Mamot, MD, Matthew Care, PhD, Christopher Pocock, Louise Stanton, PhD, Debbie Hamid, Keith Pugh, PhD, Andrew McMillan, PhD, Paul Fields, MDPhD, Anton Kruger, Andrew Jack, PhD MB, Peter W. M. Johnson, FRCP

Blood (2015) 126 (23): 812.

https://doi.org/10.1182/blood.V126.23.812.812

Published: 2015

Journal Articles

Assessment of Quality of Life in the NCRI Spirit 2 Study Comparing Imatinib with Dasatinib in Patients with Newly-Diagnosed Chronic Phase Chronic Myeloid Leukaemia

Alexander M. Labeit, MDPhD, Mhairi Copland, BSc (Hons) MB ChB PhDFRCP FRCPath, Leanne M. Cork, BSc (Hons), Corinne A. Hedgley, BSc (Hons), Letizia Foroni, MDPhDFRCPath, Wendy L. Osborne, MBBS (Hons) MRCP FRCPath, Gemma Gills, MSc BSc (Hons), Jane F. Apperley, MD, Tessa L. Holyoake, MDPhD, Ruth V. Bescoby, MSc BSc, Christopher Pocock, Thomas Zwingers, MSc, Philippa Burnell, Jenny L. Byrne, PhD, John H. McCullough, John M. Goldman, DM FRCP FRCPath, Richard E. Clark, MD, Stephen G. O'Brien, BSc (Hons) PhD MBChB FRCP MRCPath

Blood (2015) 126 (23): 4024.

https://doi.org/10.1182/blood.V126.23.4024.4024

Published: 2015

Journal Articles

Outcome of Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: Subgroup Analysis from the UK NCRI R-CHOP 14 Vs 21 Trial

Blood (2015) 126 (23): 1516.

https://doi.org/10.1182/blood.V126.23.1516.1516

Published: 2015

Journal Articles

Impact of Finding of Low Level Kinase Domain Mutations Using Ultra Deep Next Generation Sequencing in Patients with Chronic Phase CML

Aytug Kizilors, PhD, Elena Crisa, MD, Nicholas Lea, PhD, Steven Best, PhD, Mian Syed, PhD, Robin M. Ireland, FRCP, FRCPath, Maadh Aldouri, FRCPath, Christopher Pocock, Timothy Corbett, FRCP, FRCPath, Emily Elizabeth Bart-Smith, MRCP,BSc, Richard Gale, FRCPath, FRCP, Clare Wykes, FRCPath, FRCP, Simon Weston-Smith, FRCP, FRCPath, Donal McLornan, MDPhD, Antonio Pagliuca, MBBS, FRCP, FRCPath, MA, Ghulam J. Mufti, MD PhD, Hugues de Lavallade, MD PhD

Blood (2015) 126 (23): 347.

https://doi.org/10.1182/blood.V126.23.347.347

Published: 2015

Journal Articles

Hematologic and Immunologic Function and Patient Well-Being for the Phase III RESONATE TM Study of Ibrutinib Vs Ofatumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Blood (2014) 124 (21): 4696.

https://doi.org/10.1182/blood.V124.21.4696.4696

Published: 2014

Journal Articles

Risk of CNS Relapse with Diffuse Large B-Cell Lymphoma (DLBCL) in the Rituximab Era: Results from the UK NCRI R-CHOP 14 v 21 Trial

Mary Gleeson, FRCPath, David Cunningham, FMedSci, Eliza A Hawkes, MD, Wendi Qian, PhD, Paul Smith, MSc, Nick Chadwick, Paul Mouncey, MSc, Andrew Jack, PhD, Christopher Pocock, MD PhD, Kirit M Ardeshna, MD FRCPath, John Radford, Andrew McMillan, PhD, John Davies, FRCPE, Deborah Turner, FRCPath, Anton Kruger, FRCPath, Peter W.M. Johnson, FRCP, Joanna Gambell, BSc, David C Linch, FMedSci

Blood (2014) 124 (21): 1723.

https://doi.org/10.1182/blood.V124.21.1723.1723

Published: 2014

Journal Articles

Spirit 2: An NCRI Randomised Study Comparing Dasatinib with Imatinib in Patients with Newly Diagnosed CML

Stephen G O'Brien, BSc (Hons) PhD MBChB FRCP MRCPath, Corinne Hedgley, BSc, Sarah Adams, BSc MSc, Letizia Foroni, MDPhD, Jane F. Apperley, MD, Tessa L Holyoake, MDPhDFRSE FMedSci, Christopher Pocock, MD PhD, Jenny L Byrne, MB ChB PhDFRCP FRCPath, Lynn Margaret Seeley, MSc RN NDN, Wendy L Osborne, MBBS(Hons) MRCP FRCPath, John M Goldman, DM, Mhairi Copland, BSc PhDFRCP FRCPath, Richard E Clark, MA, MD

Blood (2014) 124 (21): 517.

https://doi.org/10.1182/blood.V124.21.517.517

Published: 2014

Journal Articles

A Randomized Comparison Of Maintenance Therapy With Subcutaneous Rituximab For 2 Years Versus Until Progression In Patients With Indolent Non-Hodgkin’s Lymphoma: Interim Safety Data From The Mabcute Study

Simon Rule, MD, Javier Briones, MD, Angelo Michele Carella, MD, Olivier Casasnovas, MD, Wolney Gois Barreto, MD, Christopher Pocock, PhD, Stuart Osborne, PhD, Rodney Smith, MD, Francesco Zaja, MD

Blood (2013) 122 (21): 3052.

https://doi.org/10.1182/blood.V122.21.3052.3052

Published: 2013

NARROW

Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Maintenance Trial

CC-486 Improves Overall Survival (OS) and Relapse-Free Survival (RFS) for Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC), Regardless of Amount of Consolidation Received: Results from the Phase III QUAZAR AML-001 Maintenance Trial

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

Spirit 2: Final 5 Year Analysis of the UK National Cancer Research Institute Randomized Study Comparing Imatinib with Dasatinib in Patients with Newly Diagnosed Chronic Phase CML

Minimal Residual Disease Response at End of Induction and during Maintenance Correlates with Updated Outcome in the Phase III GALLIUM Study of Obinutuzumab- or Rituximab-Based Immunochemotherapy in Previously Untreated Follicular Lymphoma Patients

Results of a Phase 2 Trial of the Monocyte-Targeted Histone Deacetylase Inhibitor Tefinostat (CHR-2845) in Chronic Myelomonocytic Leukemia (CMML) — the UK Monocle Study

Older Patients (pts) with Previously Untreated Classical Hodgkin Lymphoma (cHL): A Detailed Analysis from the Phase 3 ECHELON-1 Study

A Comparison of Prognostic Indices in Diffuse Large B-Cell Lymphoma within the UK NCRI R-CHOP 14 Versus 21 Phase III Trial

The Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma As Determined By Whole Genome Expression Profiling on Paraffin Embedded Tissue Is Independently Associated with Reduced Overall and Progression Free Survival in the Rituximab Era: Results from the UK NCRI R-CHOP 14 v 21 Phase III Trial

Updated Analysis of Overall Survival in Randomized Phase III Study of Idelalisib in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL

Chronic Myeloid Leukaemia Patients with Stable Molecular Responses (at least MR3) May Safely Decrease the Dose of Their Tyrosine Kinase Inhibitor: Data from the British Destiny Study

A Prospective Randomised Trial of Targeted Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) Based upon Real-Time Gene Expression Profiling: The Remodl-B Study of the UK NCRI and SAKK Lymphoma Groups (ISRCTN51837425)

Assessment of Quality of Life in the NCRI Spirit 2 Study Comparing Imatinib with Dasatinib in Patients with Newly-Diagnosed Chronic Phase Chronic Myeloid Leukaemia

Outcome of Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: Subgroup Analysis from the UK NCRI R-CHOP 14 Vs 21 Trial

Impact of Finding of Low Level Kinase Domain Mutations Using Ultra Deep Next Generation Sequencing in Patients with Chronic Phase CML

R-CHOP in Primary Mediastinal B-Cell Lymphoma (PMBL): Results from the UK NCRI R-CHOP 14 v 21 Trial

Hematologic and Immunologic Function and Patient Well-Being for the Phase III RESONATE TM Study of Ibrutinib Vs Ofatumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Risk of CNS Relapse with Diffuse Large B-Cell Lymphoma (DLBCL) in the Rituximab Era: Results from the UK NCRI R-CHOP 14 v 21 Trial

Spirit 2: An NCRI Randomised Study Comparing Dasatinib with Imatinib in Patients with Newly Diagnosed CML

A Randomized Comparison Of Maintenance Therapy With Subcutaneous Rituximab For 2 Years Versus Until Progression In Patients With Indolent Non-Hodgkin’s Lymphoma: Interim Safety Data From The Mabcute Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only